Prakoura Niki, Kavvadas Panagiotis, Kormann Raphaёl, Dussaule Jean-Claude, Chadjichristos Christos E, Chatziantoniou Christos
Institut National de la Santé Et de la Recherche Médicale, Unité Mixte de Recherche Scientifique 1155, Tenon Hospital, Paris, France.
Sorbonne Université, Université Pierre-et-Marie-Curie Paris 6, Paris, France; and.
J Am Soc Nephrol. 2017 May;28(5):1475-1490. doi: 10.1681/ASN.2016070709. Epub 2016 Dec 5.
expression in the kidney of periostin, a protein involved in odontogenesis and osteogenesis, has been suggested as a biomarker of renal disease. In this study, we investigated the mechanism(s) of induction and the role of periostin in renal disease. Using a combination of bioinformatics, reporter assay, and chromatin immunoprecipitation analyses, we found that NFB and other proinflammatory transcription factors induce periostin expression and that binding of these factors on the periostin promoter is enriched in glomeruli during experimental GN. Mice lacking expression of periostin displayed preserved renal function and structure during GN. Furthermore, delayed administration of periostin antisense oligonucleotides in wild-type animals with GN reversed already established proteinuria, diminished tissue inflammation, and improved renal structure. Lack of periostin expression also blunted the renal expression of integrin-3 and phosphorylation of focal adhesion kinase and AKT, known mediators of integrin-3 signaling that affect cell motility and survival, observed during GN in wild-type animals. , recombinant periostin increased the expression of integrin-3 and the concomitant phosphorylation of focal adhesion kinase and AKT in podocytes. Notably, periostin and integrin-3 were highly colocalized in biopsy specimens from patients with inflammatory GN. These results demonstrate that interplay between periostin and renal inflammation orchestrates inflammatory and fibrotic responses, driving podocyte damage through downstream activation of integrin-3 signaling. Targeting periostin may be a novel therapeutic strategy for treating CKD.
骨膜蛋白是一种参与牙发生和成骨过程的蛋白质,其在肾脏中的表达已被认为是肾脏疾病的生物标志物。在本研究中,我们调查了骨膜蛋白的诱导机制及其在肾脏疾病中的作用。通过结合生物信息学、报告基因检测和染色质免疫沉淀分析,我们发现核因子κB(NFκB)和其他促炎转录因子可诱导骨膜蛋白表达,并且在实验性肾小球肾炎(GN)期间,这些因子在骨膜蛋白启动子上的结合在肾小球中富集。缺乏骨膜蛋白表达的小鼠在GN期间肾功能和结构得以保留。此外,在患有GN的野生型动物中延迟给予骨膜蛋白反义寡核苷酸可逆转已出现的蛋白尿,减轻组织炎症,并改善肾脏结构。缺乏骨膜蛋白表达还减弱了整合素β3在肾脏中的表达以及粘着斑激酶和AKT的磷酸化,这两种蛋白是整合素β3信号通路的已知介质,在野生型动物的GN期间可观察到它们影响细胞运动和存活。此外,重组骨膜蛋白增加了足细胞中整合素β3的表达以及粘着斑激酶和AKT的伴随磷酸化。值得注意的是,在炎症性GN患者的活检标本中,骨膜蛋白和整合素β3高度共定位。这些结果表明,骨膜蛋白与肾脏炎症之间的相互作用协调了炎症和纤维化反应,通过整合素β3信号通路的下游激活驱动足细胞损伤。靶向骨膜蛋白可能是治疗慢性肾脏病(CKD)的一种新的治疗策略。